IVADANTIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Ivadantin, and when can generic versions of Ivadantin launch?
Ivadantin is a drug marketed by Procter And Gamble and is included in one NDA.
The generic ingredient in IVADANTIN is nitrofurantoin sodium. There are twenty drug master file entries for this compound. Additional details are available on the nitrofurantoin sodium profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for IVADANTIN?
- What are the global sales for IVADANTIN?
- What is Average Wholesale Price for IVADANTIN?
Summary for IVADANTIN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 98 |
| DailyMed Link: | IVADANTIN at DailyMed |
US Patents and Regulatory Information for IVADANTIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Procter And Gamble | IVADANTIN | nitrofurantoin sodium | INJECTABLE;INJECTION | 012402-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
